Please login to the form below

Not currently logged in
Email:
Password:

Retrophin

This page shows the latest Retrophin news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets. Sparsentan has potential to become a blockbuster FSG drug, according to analysts. ... What a difference a year makes. Under pressure in 2015, US firm Retrophin now has a positive trial in hand

Latest news

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    More recently Retrophin sold its PRV to Sanofi for $245m, so it looks as though values are definitely on the rise!

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi purchased the paediatric PRV from Retrophin for the total consideration of $245m ($150m on closure with two subsequent payments in 2016 and 2017 of $47.7m). ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam

  • Pharma deals during February 2014 Pharma deals during February 2014

    Recently public, Retrophin has acquired Manchester Pharmaceuticals, a speciality pharmaceutical company that focuses on treatments for rare diseases. ... Retrophin is paying a total of $62.5m, including an upfront of $29.5m, plus royalties based on

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Licence termination. DiaPep277 for type 1 diabetes patients. 72. Manchester Pharmaceuticals / Retrophin.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Amryt Pharma appoints new regulatory affairs head Amryt Pharma appoints new regulatory affairs head

    Amryt Pharma appoints new regulatory affairs head. Derval O’Carroll joins the rare disease-focused biopharma from Retrophin. ... Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics